MX2023004102A - Derivado de gamma-carbolina fusionado sustituido con heterociclo, metodo de preparacion del mismo, intermediarios del mismo y uso del mismo. - Google Patents

Derivado de gamma-carbolina fusionado sustituido con heterociclo, metodo de preparacion del mismo, intermediarios del mismo y uso del mismo.

Info

Publication number
MX2023004102A
MX2023004102A MX2023004102A MX2023004102A MX2023004102A MX 2023004102 A MX2023004102 A MX 2023004102A MX 2023004102 A MX2023004102 A MX 2023004102A MX 2023004102 A MX2023004102 A MX 2023004102A MX 2023004102 A MX2023004102 A MX 2023004102A
Authority
MX
Mexico
Prior art keywords
substituted fused
preparation
heterocyclic substituted
method therefor
carboline derivative
Prior art date
Application number
MX2023004102A
Other languages
English (en)
Inventor
Zehong Wan
Jiaquan Feng
Yongqi Wu
Jun Qin
Bingcheng Zhou
Zhijing Hu
Xinjian Jiang
Zijin Feng
Original Assignee
Shujing Biopharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shujing Biopharma Co Ltd filed Critical Shujing Biopharma Co Ltd
Publication of MX2023004102A publication Critical patent/MX2023004102A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/16—Peri-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Addiction (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La presente invención se refiere a un derivado de ?-carbolina fusionado sustituido con heterociclo, un método de preparación del mismo, un intermediario del mismo y el uso del mismo; el derivado de ?-carbolina fusionado sustituido con heterociclo tiene una estructura de compuesto representada por la fórmula (I); este compuesto se puede usar para preparar un medicamento para el tratamiento de enfermedades neuropsiquiátricas. (ver Fórmula).
MX2023004102A 2020-10-09 2021-10-08 Derivado de gamma-carbolina fusionado sustituido con heterociclo, metodo de preparacion del mismo, intermediarios del mismo y uso del mismo. MX2023004102A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN202011074344 2020-10-09
CN202011075840 2020-10-09
PCT/CN2021/122546 WO2022073470A1 (zh) 2020-10-09 2021-10-08 杂环取代的稠合γ-咔啉类衍生物、其制备方法、中间体及应用

Publications (1)

Publication Number Publication Date
MX2023004102A true MX2023004102A (es) 2023-04-27

Family

ID=81125599

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023004102A MX2023004102A (es) 2020-10-09 2021-10-08 Derivado de gamma-carbolina fusionado sustituido con heterociclo, metodo de preparacion del mismo, intermediarios del mismo y uso del mismo.

Country Status (11)

Country Link
US (1) US20230339949A1 (es)
EP (1) EP4227306A4 (es)
JP (1) JP2023544653A (es)
KR (1) KR20230054417A (es)
CN (1) CN116568302A (es)
AU (1) AU2021356875B2 (es)
BR (1) BR112023005443A2 (es)
CA (1) CA3194682A1 (es)
IL (1) IL301847A (es)
MX (1) MX2023004102A (es)
WO (1) WO2022073470A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024088285A1 (zh) * 2022-10-26 2024-05-02 上海枢境生物科技有限公司 一种杂环取代的稠合γ-咔啉类衍生物的甲磺酸盐、晶型及其制备方法和应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60014083T2 (de) * 1999-06-15 2006-03-02 Bristol-Myers Squibb Pharma Co., Wilmington Substituierte heterocyclylkondensierte gamma carboline
CN105168219B (zh) * 2008-05-27 2018-11-20 细胞内治疗公司 用于睡眠障碍和其他疾病的方法和组合物
KR20220054908A (ko) * 2014-04-04 2022-05-03 인트라-셀룰라 써래피스, 인코퍼레이티드. 유기 화합물
WO2017117514A1 (en) * 2015-12-31 2017-07-06 Tung Roger D Deuterated iti-007
IL296884B2 (en) * 2016-01-26 2024-05-01 Intra Cellular Therapies Inc Condensed heterocyclic converted gamma carbonyls for use in the treatment of central nervous system disorders
BR112019019875A2 (pt) * 2017-03-24 2020-04-22 Intra Cellular Therapies Inc novas composições e métodos

Also Published As

Publication number Publication date
CA3194682A1 (en) 2022-04-14
AU2021356875A1 (en) 2023-05-25
JP2023544653A (ja) 2023-10-24
KR20230054417A (ko) 2023-04-24
CN116568302A (zh) 2023-08-08
AU2021356875B2 (en) 2023-11-23
AU2021356875A9 (en) 2024-02-08
EP4227306A4 (en) 2024-02-28
EP4227306A1 (en) 2023-08-16
BR112023005443A2 (pt) 2023-05-09
IL301847A (en) 2023-06-01
US20230339949A1 (en) 2023-10-26
WO2022073470A1 (zh) 2022-04-14

Similar Documents

Publication Publication Date Title
MX2022008066A (es) Compuestos triciclicos sustituidos.
MX2021006283A (es) Derivados heteroaromáticos para uso como regulador, método de preparación de los mismos y uso de los mismos.
SG11201810655QA (en) Method for producing substituted polycyclic pyridone derivative and crystal of same
MX2022006475A (es) Compuestos triciclicos sustituidos.
EA201991693A1 (ru) Производное пиридина в качестве ингибитора ask1 и способ его получения и применения
TN2018000395A1 (en) New (hetero)aryl-substituted-piperidinyl derivatives, a process for their preparation and pharmaceutical compositions containing them
PH12020552017A1 (en) 2,3-dihydro-1h-pyrrolizine-7-formamide derivative and application thereof
MX2020007265A (es) Derivados de rapamicina.
TN2019000204A1 (en) Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same
PH12021550825A1 (en) Quinoline derivatives as alpha4beta7 integrin inhibitors
MX2022001784A (es) Piperidinil-metil-purinaminas como inhibidores de nsd2 y antineoplásicos.
PH12020550905A1 (en) Process for preparing antihelmintic 4-amino-quinoline-3-carboxamide derivatives
SA520411635B1 (ar) A2a مشتق حلقي مدمج كمثبط مستقبل
MX2020002449A (es) Nuevos compuestos heterociclicos fungicidas.
MX2021010122A (es) Compuestos de imidazopiridinilo y su uso para el tratamiento de trastornos neurodegenerativos.
MX2016000669A (es) Compuestos plaguicidas.
MX2022000945A (es) Composicion para incrementar la expresion de pgc-1alfa.
MX2021002188A (es) Nuevo derivado de amina heterociclica y composicion farmaceutica que la comprende.
MX2021003739A (es) Derivados de quinolino-pirrolidin-2-ona como inhibidores del gen mutado de ataxia telangiectasia (atm) y el uso de los mismos en el tratamiento de tumores sólidos.
MX2021012105A (es) Compuestos de pirrol.
MX2022007670A (es) Compuestos antihelminticos que comprenden una estructura de quinolina.
PH12020552186A1 (en) Cyanotriazole compounds and uses thereof
MX2021009971A (es) Compuesto heterociclico, composicion farmaceutica que lo comprende, metodo para su preparacion, y uso de estos.
MX2023004102A (es) Derivado de gamma-carbolina fusionado sustituido con heterociclo, metodo de preparacion del mismo, intermediarios del mismo y uso del mismo.
MX2018016339A (es) Compuestos heterociclicos antiinfecciosos y sus usos.